Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Collegium Pharmaceutical
COLL
5
Enerpac Tool
EPAC
(Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -6.15%2.12B | -6.59%8.81B | -6.85%2.1B | -5.66%2.22B | -6.48%2.24B | -7.34%2.26B | -0.13%9.43B | -5.74%2.25B | -4.16%2.35B | 1.44%2.39B |
Operating revenue | -6.15%2.12B | -6.59%8.81B | -6.85%2.1B | -5.66%2.22B | -6.48%2.24B | -7.34%2.26B | -0.13%9.43B | -5.74%2.25B | -4.16%2.35B | 1.44%2.39B |
Cost of revenue | -3.35%1.68B | -6.37%6.85B | -6.06%1.64B | -4.72%1.71B | -6.89%1.76B | -7.72%1.73B | -3.93%7.31B | -7.76%1.75B | -7.27%1.8B | -1.62%1.89B |
Gross profit | -15.40%445M | -7.32%1.96B | -9.58%453M | -8.73%502M | -4.94%481M | -6.07%526M | 15.68%2.12B | 2.04%501M | 7.63%550M | 14.74%506M |
Operating expense | -8.23%212M | -3.57%838M | -6.53%186M | -11.49%208M | -3.18%213M | 7.44%231M | 9.58%869M | -8.72%199M | 12.44%235M | 17.65%220M |
Selling and administrative expenses | -8.84%196M | -3.85%774M | -6.56%171M | -13.18%191M | -3.90%197M | 9.14%215M | 4.01%805M | -10.73%183M | 8.37%220M | 10.81%205M |
Other operating expenses | 0.00%16M | 0.00%64M | -6.25%15M | 13.33%17M | 6.67%16M | -11.11%16M | 236.84%64M | 23.08%16M | 150.00%15M | 650.00%15M |
Operating profit | -21.02%233M | -9.94%1.12B | -11.59%267M | -6.67%294M | -6.29%268M | -14.49%295M | 20.35%1.25B | 10.62%302M | 4.30%315M | 12.60%286M |
Net non-operating interest income expense | 13.56%-51M | 3.77%-230M | 10.17%-53M | 6.45%-58M | 0.00%-60M | -1.72%-59M | -21.32%-239M | -9.26%-59M | -16.98%-62M | -25.00%-60M |
Non-operating interest expense | -13.56%51M | -3.77%230M | -10.17%53M | -6.45%58M | 0.00%60M | 1.72%59M | 21.32%239M | 9.26%59M | 16.98%62M | 25.00%60M |
Other net income (expense) | 33.33%-12M | 89.61%-8M | -123.08%-29M | 41.38%-17M | 394.74%56M | -12.50%-18M | 37.90%-77M | -333.33%-13M | -314.29%-29M | 81.19%-19M |
Special income (charges) | 29.41%-12M | 93.24%-5M | -133.33%-28M | 42.86%-16M | 394.74%56M | -13.33%-17M | 43.51%-74M | -140.00%-12M | -211.11%-28M | 81.37%-19M |
-Less:Restructuring and merger&acquisition | 40.00%14M | 9.80%56M | 500.00%8M | -42.31%15M | 12.50%18M | -9.09%10M | 54.55%51M | ---2M | 225.00%26M | 60.00%16M |
-Less:Other special charges | -160.00%-3M | 66.67%15M | ---- | ---- | ---- | --5M | 350.00%9M | ---- | ---- | ---- |
-Gain on sale of business | 50.00%-1M | 571.43%66M | 0.00%-5M | 50.00%-1M | 2,566.67%74M | 50.00%-2M | 85.42%-14M | -66.67%-5M | -100.00%-2M | 96.74%-3M |
Other non- operating income (expenses) | ---- | 0.00%-3M | 0.00%-1M | 0.00%-1M | ---- | 0.00%-1M | -142.86%-3M | -150.00%-1M | -150.00%-1M | ---- |
Income before tax | -22.02%170M | -4.94%886M | -19.57%185M | -2.23%219M | 27.54%264M | -19.56%218M | 30.17%932M | 6.48%230M | -7.44%224M | 97.14%207M |
Income tax | -18.87%43M | 9.05%229M | 34.29%47M | 1.85%55M | 29.82%74M | -17.19%53M | 8.25%210M | -41.67%35M | 10.20%54M | 46.15%57M |
Earnings from equity interest net of tax | ---- | 0.00%1M | --0 | --1M | ---- | ---- | --1M | --1M | --0 | ---- |
Net income | -23.03%127M | -8.99%658M | -29.59%138M | -2.94%165M | 26.67%190M | -20.29%165M | 38.51%723M | 25.64%196M | -11.92%170M | 127.27%150M |
Net income continuous Operations | -23.03%127M | -8.99%658M | -29.59%138M | -2.94%165M | 26.67%190M | -20.29%165M | 38.51%723M | 25.64%196M | -11.92%170M | 127.27%150M |
Minority interest income | ||||||||||
Net income attributable to the parent company | -23.03%127M | -8.99%658M | -29.59%138M | -2.94%165M | 26.67%190M | -20.29%165M | 38.51%723M | 25.64%196M | -11.92%170M | 127.27%150M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -23.03%127M | -8.99%658M | -29.59%138M | -2.94%165M | 26.67%190M | -20.29%165M | 38.51%723M | 25.64%196M | -11.92%170M | 127.27%150M |
Basic earnings per share | -22.22%0.42 | -8.09%2.16 | -28.13%0.46 | 0.00%0.55 | 26.53%0.62 | -19.40%0.54 | 39.05%2.35 | 25.49%0.64 | -12.70%0.55 | 133.33%0.49 |
Diluted earnings per share | -20.75%0.42 | -7.69%2.16 | -28.13%0.46 | 0.00%0.55 | 26.53%0.62 | -20.90%0.53 | 38.46%2.34 | 28.00%0.64 | -11.29%0.55 | 133.33%0.49 |
Dividend per share | 10.00%0.11 | 0.00%0.4 | 0.00%0.1 | 0.00%0.1 | 0.00%0.1 | 0.00%0.1 | 23.08%0.4 | 0.00%0.1 | 33.33%0.1 | 33.33%0.1 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |